Clinical outcomes of a real‐world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day
Jackie Elliott, Chloe Husband, Heydar Khadem, Hoda Nemat, Lucy Cardno, Laura Currin, Susan Hudson Abstract
Aims
This study assessed real‐world glycaemic outcomes associated with the use of Dexcom ONE in adults with suboptimally controlled diabetes.
Methods
In this single‐site prospective study, adults with type 1 (T1D) or type 2 diabetes (T2D) taking two or more insulin injections per day initiated Dexcom ONE CGM use and attended follow‐up data collection visits after 3 and 6 months. During the study, participants received usual diabetes care. Primary outcome was a change in HbA1c at 6 months. Additional outcomes included change in participant‐reported outcomes and CGM‐derived time in glucose range 3.9–10 mmol/L (TIR), time above range >10 mmol/L (TAR), and time below range <3.9 mmol/L (TBR).
Results
There were 110 adults enrolled [T1D (n = 34): mean age 36.6 years, 55.9% female; T2D (n = 76): mean age 54.9 years, 38.2% female]. Mean HbA1c significantly decreased from 90 mmol/mol (10.3%) to 79 mmol/mol (9.4%) at 6 months (∆‐12 mmol/mol, p < 0.001) in T1D users and from 86 mmol/mol (10.1%) to 67 mmol/mol (8.3%) in T2D users (∆‐18 mmol/mol, p < 0.001). Perception of health and diabetes distress improved at 6 months for both groups. T1D users had modest improvement in TBR. T2D users exhibited a clinically meaningful increase in TIR (∆ + 9.0%).
Conclusion
Real‐world Dexcom ONE use was associated with clinically significant reductions in mean HbA1c after 6 months, along with meaningful improvements in participant‐reported outcomes. CGM‐derived outcomes also improved, with the possibility of there being greater improvement than could be captured in this study. These findings support expanding access to this real‐time CGM system.